Cumulative 2014/2015 Season Lot Release Status (Updated 12/23/2014)
Flu vaccine lots that have been released by FDA and are available for distribution by the manufacturers. For information on flu vaccine distribution schedules, please contact the manufacturers directly.
|Manufacturer||Total Number of Lots Released by FDA|
|AFLURIA - CSL Limited||52|
|Fluarix - GlaxoSmithKline Biologicals||6|
|Fluarix Quadrivalent - GlaxoSmithKline Biologicals||29|
|Flublok - Protein Sciences Corporation||12|
|Flucelvax - Novartis Vaccines and Diagnostics, Inc.||18|
|FluLaval - ID Biomedical Corp. of Quebec||9|
|FluLaval Quadrivalent - ID Biomedical Corp.||19|
|FluMist Quadrivalent - MedImmune, LLC||34|
|Fluvirin - Novartis Vaccines and Diagnostics Limited||56|
|Fluzone - Sanofi Pasteur, Inc.||38|
|Fluzone Quadrivalent - Sanofi Pasteur, Inc.||32|
FDA's Vaccines and Related Biological Products Advisory Committee (VRBPAC) met in Silver Spring, Maryland, on February 28, 2014, to select the influenza viruses for the composition of the influenza vaccine for the 2014-2015 U.S. influenza season. During this meeting, the advisory committee reviewed and evaluated the surveillance data related to epidemiology and antigenic characteristics of recent influenza isolates, serological responses to 2013-2014 vaccines, and the availability of candidate strains and reagents.
The committee recommended that the trivalent formulation influenza vaccines for the U.S. 2014-2015 influenza season contain the following:
- an A/California/7/2009 (H1N1)-like virus;
- an (H3N2) virus antigenically like the cell-propagated prototype virus A/Victoria/361/2011;
- a B/Massachusetts/2/2012-like virus.
The committee also recommended that quadrivalent influenza vaccines contain the above three strains and the following additional B strain:
- a B/Brisbane/60/2008-like virus